BNKL — Bionik Laboratories Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $1.73m
- $1.81m
Annual cashflow statement for Bionik Laboratories, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.6 | -25 | -13.6 | -10.4 | -4.95 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 2.46 | 16.1 | 8.41 | 6.02 | 0.482 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.49 | -0.571 | 0.399 | 0.14 | 1.01 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -9.23 | -9.06 | -4.62 | -4.15 | -3.39 |
| Capital Expenditures | -0.102 | -0.16 | 0 | -0.013 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | -0.224 |
| Acquisition of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.102 | -0.16 | 0 | -0.013 | -0.224 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.27 | 11 | 2.96 | 5.55 | 2.05 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.061 | 1.82 | -1.66 | 1.38 | -1.56 |